Manoela Astolfi Vivan

Dr. Manoela Astolfi Vivan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2020 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
NKNatália Luiza Kops
Natália Luiza Kops
MVManoela Astolfi Vivan
Manoela Astolfi Vivan
EFElisa Ruiz Fülber
Elisa Ruiz Fülber
MFMarco Fleuri
Marco Fleuri
JFJulia Fagundes
Julia Fagundes
RFRogerio Friedman
Rogerio Friedman

25 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MVManoela Astolfi Vivan
Manoela Astolfi Vivan
NKNatalia Luiza Kops
Natalia Luiza Kops
EFElisa Ruiz Fülber
Elisa Ruiz Fülber
ASAnderson Castro de Souza
Anderson Castro de Souza
MFMarco Aurélio Santana Batista Fleuri
Marco Aurélio Santana Batista Fleuri
RFRogerio Friedman
Rogerio Friedman

1 August 2020 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
NKNatalia Luiza Kops
Natalia Luiza Kops
MVManoela Astolfi Vivan
Manoela Astolfi Vivan
MCMariana L. Dias de Castro
Mariana L. Dias de Castro
JHJaqueline D. Correia Horvath
Jaqueline D. Correia Horvath
FCFabiana Silva Costa
Fabiana Silva Costa
RFRogerio Friedman
Rogerio Friedman

2 September 2022 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
MVManoela Astolfi Vivan
Manoela Astolfi Vivan
BRBrenda Rigatti
Brenda Rigatti
SCSainan Voss da Cunha
Sainan Voss da Cunha
GFGuilherme Cristianetti Frison
Guilherme Cristianetti Frison
LALucas Quadros Antoniazzi
Lucas Quadros Antoniazzi
RSRenato Seligman
Renato Seligman
D-dimer levels are significantly higher in COVID-19 patients with Pulmonary Thromboembolism (PTE) as compared to those without PTE, but its clinical utility is still uncertain. To determine the D-dimer performance for ruling out PTE in patients with COVID-19. We also assessed clinical and laboratory factors associated with the presence of PTE on CT Pulmonary Angiogram (CTPA). Retrospective study involving all patients who presented at a tertiary care hospital from March 2020 to May 2021 with severe acute respiratory syndrome from COVID-19, who underwent CTPA and had D-dimer collected within 48 hours from CTPA. The D-dimer ability to classify patients with or without PTE according to CTPA was evaluated. A total of 697 patients [382 (54.8%) men; mean (SD) age, 59 (20.5) years] were included, of which 71.5% required intensive care admission, 32.4% had PTE, and 35.6% died during hospitalization. PTE was independently associated with mortality [42.5% vs. 32.3%; p = 0.038]. D-dimer levels were higher in patients with PTE [9.1 (3.9; 20) vs. 2.3 (1.2; 5.1); p < 0.001]. Using the D-dimer cutoff of 0.5 μg/mL or above, sensitivity was 98.2% and specificity 5.7%. The 0.3 μg/mL threshold was associated with 100% of sensitivity for the presence of PTE, with which 99.1% of patients had increased values. ROC curve AUC was 0.77, demonstrating moderate discriminative power of D-dimers to detect PTE. D-dimer levels are higher among COVID-19 hospitalized patients with PTE as compared to those without PTE and have moderate discriminative power to detect PTE, but its use to exclude PTE in this population may have limited clinical utility.

1 June 2024 in Brazilian Journal of Nephrology
Verified
Journal Article
Open access
ARAndré Lucas Ribeiro
André Lucas Ribeiro
FSFabricio Bergelt de Sousa
Fabricio Bergelt de Sousa
BJBeatriz Cavalcanti Juchem
Beatriz Cavalcanti Juchem
AZAndré Zimerman
André Zimerman
GBGuilherme Bernardi
Guilherme Bernardi
TGTiago Severo Garcia
Tiago Severo Garcia
Introduction: Contrast-associated acute kidney injury (CA-AKI) is a deterioration of kidney function that occurs after the administration of a iodinated contrast medium (ICM). Most studies that defined this phenomenon used older ICMs that were more prone of causing CA-AKI. In the past decade, several articles questioned the true incidence of CA-AKI. However, there is still a paucity of a data about the safety of newer ICM. Objective: To assess the incidence of CA-AKI in hospitalized patients that were exposed to computed tomography (CT) with and without ICM. Methods: Prospective cohort study with 1003 patients who underwent CT in a tertiary hospital from December 2020 through March 2021. All inpatients aged > 18 years who had a CT scan during this period were screened for the study. CA-AKI was defined as a relative increase of serum creatinine of ≥ 50% from baseline or an absolute increase of ≥ 0.3 mg/dL within 18 to 48 hours after the CT. Chi-squared test, Kruskal-Wallis test, and linear regression model with restricted cubic splines were used for statistical analyses. Results: The incidence of CA-AKI was 10.1% in the ICM-exposed group and 12.4% in the control group when using the absolute increase criterion. The creatinine variation from baseline was not significantly different between groups. After adjusting for baseline factors, contrast use did not correlate with worse renal function. Conclusion: The rate of CA-AKI is very low, if present at all, with newer ICMs, and excessive caution regarding contrast use is probably unwarranted.

5 August 2021 in International Archives of Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
JGJoão Pedro T. Garcia
João Pedro T. Garcia
BMBianca H. de Moura
Bianca H. de Moura
VRVinícius H. Rodrigues
Vinícius H. Rodrigues
MVManoela Astolfi Vivan
Manoela Astolfi Vivan
SASimone M. de Azevedo
Simone M. de Azevedo
MLMichelle Lavinsky-Wolff
Michelle Lavinsky-Wolff
Introduction Inferior turbinate surgery is often performed concomitantly with rhinoseptoplasty. As inferior turbinates play a major role in allergic rhinitis, it seems reasonable to suggest that inferior turbinate surgery reduces allergy. Objective To assess the impact of nasal turbinate surgery on non-obstructive allergic symptoms (nasal discharge, sneezing, pruritus, and allergic conjunctivitis) and on the use of allergic medication in patients with allergic rhinitis undergoing rhinoseptoplasty. Methods Secondary analysis of aggregated data from two randomized controlled trials. Participants with allergic rhinitis aged ≥ 16 years were recruited. Data from two groups were analyzed: patients with rhinoseptoplasty and concomitant turbinate reduction (intervention group) and patients with rhinoseptoplasty only (control group). The 90-day postoperative frequency of non-obstructive allergic symptoms and of nasal steroid and oral antihistamine use were analyzed. Results A total of 100 patients were studied. The groups were similar in terms of allergic symptom intensity and mean age. The frequency of non-obstructive allergic symptoms decreased 90 days postoperative in both groups (p < 0.01). There was no difference between the groups in the frequency of non-obstructive allergic symptoms at 90 days (p = 0.835). Topical nasal steroid and oral histamine antagonist use decreased in the intervention group at 90 days (p < 0.05). Conclusions Ninety days after the surgery, turbinate reduction performed in association with rhinoseptoplasty did not reduce the frequency of non-obstructive allergic symptoms more than rhinoplasty alone. However, the observed decrease in nasal steroid and oral antihistamine use suggests an impact of turbinate reduction on medication use in patients with allergic rhinitis undergoing rhinoseptoplasty. Trial Registration ClinicalTrials.gov database (NCT01457638 and NCT02231216).